Prostate-specific membrane antigen (PSMA) imaging is a nuclear medicine exam using positron emission tomography (PET) to detect prostate cancer. This PSMA PET scan is investigational and is very sensitive for detecting prostate cancer, with accumulating evidence suggesting it is superior to conventional imaging tests such as CT scans or bone scans. 

The advent of prostate specific membrane antigen (PSMA) positron emission tomography (PET) imaging has revolutionized radiation therapy of prostate cancer.  Current radiation therapy treatment schedules for prostate cancer have been established by randomized trials using statistical risk calculations, nomograms and conventional imaging for patient characterization and treatment.  PSMA-PET bears the promise of delivering individually tailored radiation therapy for prostate cancer.